The Hotel-Dieu de Québec is a teaching hospital located in Quebec City, Quebec, Canada, and affiliated with Université Laval's medical school. It is part of the Centre hospitalier universitaire de Québec, a network of five teaching hospitals and several specialized institutions.

During the past decade, CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ) conducted 49 clinical trials. In the 10-year time frame, 49 clinical trials started and 42 clinical trials were completed, i.e. on average, 85.7% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 26 clinical trials were completed. i.e. 173.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)" #1 sponsor was "Canadian Cancer Trials Group" with 14 trials, followed by "NCIC Clinical Trials Group" with 13 trials sponsored, "Radiation Therapy Oncology Group" with 8 trials sponsored, "CHU de Quebec-Universite Laval" with 7 trials sponsored and "NRG Oncology" with 7 trials sponsored. Other sponsors include 75 different institutions and companies that sponsored additional 50 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)" #1 collaborator was "National Cancer Institute (NCI)" with 27 trials as a collaborator, "NRG Oncology" with 11 trials as a collaborator, "Canadian Institutes of Health Research (CIHR)" with 8 trials as a collaborator, "Canadian Cancer Trials Group" with 7 trials as a collaborator and "SWOG Cancer Research Network" with 7 trials as a collaborator. Other collaborators include 135 different institutions and companies that were collaborators in the rest 102 trials.

According to Clinical.Site data, the most researched conditions in "CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)" are "Prostate Cancer" (23 trials), "Breast Cancer" (7 trials), "Colorectal Cancer" (5 trials), "Multiple Myeloma" (5 trials) and "Bladder Cancer" (3 trials). Many other conditions were trialed in "CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)" in a lesser frequency.

Most popular intervention types in "CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)" are "Drug" (83 trials), "Radiation" (43 trials), "Other" (26 trials), "Procedure" (13 trials) and "Biological" (12 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "Quality-of-Life Assessment" (7 trials), "Cisplatin" (6 trials), "cisplatin" (6 trials) and "Enzalutamide" (5 trials). Other intervention names were less common.

The vast majority of trials in "CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)" are 77 trials for "All" genders, 32 trials for "Male" genders and 20 trials for "Female" genders.

Currently, there are NaN active trials in "CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)". 1 are not yet recruiting, 18 are recruiting, 32 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 63 completed trials in CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ), undefined suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ), 3 "Phase 1" clinical trials were conducted, 30 "Phase 2" clinical trials and 74 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 20 trials that are defined as “Not Applicable".